Alzheimer's disease: The strength of association of costs with different measures of disease severity
- 238 Downloads
To identify Alzheimer's disease (AD) severity measures for use in cost-effectiveness models that effectively capture the impact of AD on costs.
A review of the literature and data abstraction from papers that present 1) mean AD costs (direct, indirect, or total) by disease severity, defined using measure of cognition, functional status, and behavior; and/or 2) the results of regression analyses that estimate the strength of the association between AD costs and disease severity.
All papers reviewed showed that mean total costs increase with disease severity regardless of severity-measurement method. The relative difference in mean total costs between patients with severe disease compared to those with moderate disease, or moderate disease compared to mild disease, was fairly consistent across studies, suggesting that any of the disease-severity measures may be used to broadly categorize patients by cost. However, when regression analysis included multiple disease-severity measures, independent associations with costs were noted for the different measures. Cognitive and functional status measures were consistently associated with direct costs, whereas functional status and behavioral measures were consistently associated with indirect costs and caregiver hours.
Either multidimensional disease-severity measures, or a single disease-severity measure, that capture the impact of cognition, functional status, and behavior on costs are needed for cost-effectiveness models.
Key wordsAlzheimer's disease disease severity cognition functional status behavior costs
Unable to display preview. Download preview PDF.
- 6.Fenn P, Gray A: Estimating the long term cost savings from treatment of Alzheimer's disease: a modeling approach. Pharmacoeconomics 1999, (2): 165–174.Google Scholar
- 10.Caro JJ, Salas M, Ward A, Getsios D, Mehnert A, the AHEAD Study Group: Assessment of health economics in Alzheimer's Disease. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 2002, 14(2): 84–89.CrossRefPubMedGoogle Scholar
- 16.Birks J: Cholinesterase inhibitors for Alzheimer's disease [review]. Cochrane Database System Rev 2006, 1. Art. No. CD005593. DOI: 10.1002/14651858.CD005593.Google Scholar
- 21.Boada M, Pena-Casanova J, Bermejo F, Guillén F, Hart WM, Espinosa C, Rovira J: Costs of health care resources of ambulatory care patients diagnosed with Alzheimer's disease in Spain. Med Clin (Barc) 1999,113: 690–695.Google Scholar
- 24.Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S: Relation between severity of Alzheimer's disease and costs of caring. Can Med Assoc J 1998, 159: 457–465.Google Scholar
- 35.López-Pousa S, Garre-Olmo J, Turon-Estrada A, Hernández F, Expósito I, Lozano-Gallego M, Hernández-Ferrándiz M, Gelada-Batlle E, Pericot-Nierga I, Vilalta-Franch J: Cost relation between severity of Alzheimer's disease and cognitive and functional impairment. Med Clin (Barc) 2004, 122: 767–772.CrossRefGoogle Scholar
- 39.Nordberg G, Wimo A, Jönsson L, Sjölund B-M, Lagergren M, von Strauss E: Time use and costs of institutionalized elderly person with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project- a population based study in Sweden. Int J Geriatr Psychiatry 2007, 22: 639–648.CrossRefPubMedGoogle Scholar
- 44.Taylor DH, Schenkman M, Zhou J, Sloan FA: The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly persons. J Gerontol 2001, 56B: S285–S293.Google Scholar